UA116008C2 - Антитіло проти підгрупи elr+ cxc-хемокінів - Google Patents

Антитіло проти підгрупи elr+ cxc-хемокінів

Info

Publication number
UA116008C2
UA116008C2 UAA201508673A UAA201508673A UA116008C2 UA 116008 C2 UA116008 C2 UA 116008C2 UA A201508673 A UAA201508673 A UA A201508673A UA A201508673 A UAA201508673 A UA A201508673A UA 116008 C2 UA116008 C2 UA 116008C2
Authority
UA
Ukraine
Prior art keywords
elr
gro
pan
cxc chemokine
chemokine antibodies
Prior art date
Application number
UAA201508673A
Other languages
English (en)
Inventor
Кетрін Бротігем Бейдлер
Крістін Кей Кіклі
Бет Енн Стріфлер
Деррік Райан Уітчер
Джефрі Стрітмен Бойлес
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA116008C2 publication Critical patent/UA116008C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Винахід належить до антитіла, яке специфічно зв'язують сім людських ELR+CXC-хемокінів, а саме: Gro-альфа, Gro-бета, Gro-гамма, ENA-78, GCP-2, NAP-2 та IL-8, молекули ДНК, клітини-хазяїна та способу лікування неспецифічного виразкового коліту, раку нирки або раку яєчників шляхом введення такого антитіла.
UAA201508673A 2013-03-15 2014-05-03 Антитіло проти підгрупи elr+ cxc-хемокінів UA116008C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792800P 2013-03-15 2013-03-15
PCT/US2014/020605 WO2014149733A1 (en) 2013-03-15 2014-03-05 Pan-ELR+ CXC CHEMOKINE ANTIBODIES

Publications (1)

Publication Number Publication Date
UA116008C2 true UA116008C2 (uk) 2018-01-25

Family

ID=50343858

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201508673A UA116008C2 (uk) 2013-03-15 2014-05-03 Антитіло проти підгрупи elr+ cxc-хемокінів

Country Status (36)

Country Link
EP (3) EP3608336A1 (uk)
JP (1) JP6105146B2 (uk)
KR (1) KR101745230B1 (uk)
CN (2) CN109134652B (uk)
AP (1) AP2015008731A0 (uk)
AR (2) AR094960A1 (uk)
AU (1) AU2014237898B2 (uk)
CA (1) CA2901468C (uk)
CL (1) CL2015002531A1 (uk)
CY (1) CY1120459T1 (uk)
DK (1) DK2970447T3 (uk)
EA (1) EA029965B1 (uk)
ES (2) ES2769123T3 (uk)
HK (1) HK1212714A1 (uk)
HR (1) HRP20181047T1 (uk)
HU (1) HUE038834T2 (uk)
IL (2) IL241167B (uk)
JO (1) JO3580B1 (uk)
LT (1) LT2970447T (uk)
MA (1) MA38413A1 (uk)
ME (1) ME03094B (uk)
MX (1) MX364831B (uk)
MY (1) MY171213A (uk)
NZ (1) NZ711704A (uk)
PE (2) PE20191480A1 (uk)
PH (1) PH12015502090B1 (uk)
PL (1) PL2970447T3 (uk)
PT (1) PT2970447T (uk)
RS (1) RS57291B1 (uk)
SG (1) SG11201507686TA (uk)
SI (1) SI2970447T1 (uk)
TN (1) TN2015000377A1 (uk)
TR (1) TR201807613T4 (uk)
TW (1) TWI612059B (uk)
UA (1) UA116008C2 (uk)
WO (1) WO2014149733A1 (uk)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911600A1 (en) * 2013-05-17 2014-11-20 Centre National De La Recherche Scientifique (Cnrs) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
CN111770936A (zh) 2018-01-12 2020-10-13 百时美施贵宝公司 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症
KR102049180B1 (ko) * 2018-04-02 2019-11-26 고려대학교 산학협력단 체세포에서 유도 만능 줄기세포로의 역분화 유도용 조성물 및 이를 이용한 역분화 유도방법
TWI737000B (zh) 2018-10-22 2021-08-21 美商美國禮來大藥廠 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
WO2021163031A1 (en) * 2020-02-12 2021-08-19 Eli Lilly And Company Crystallization of antibodies or antigen-binding fragments
TW202206457A (zh) 2020-04-24 2022-02-16 美商美國禮來大藥廠 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
WO2007107003A1 (en) * 2006-03-22 2007-09-27 Osteopharm Inc. Markers for the diagnosis, monitoring and prognosis of osteoporosis and for assessing the risk for osteoporosis and for osteoporotic fractures
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
PT2195023T (pt) * 2007-08-29 2018-06-08 Sanofi Sa Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações
GB0806812D0 (en) * 2008-04-15 2008-05-14 Univ Leuven Kath Citrullinated cytokines
CN102027015A (zh) * 2008-05-14 2011-04-20 伊莱利利公司 抗cxcr4抗体
PT2470671E (pt) * 2009-08-28 2015-02-05 Regeneron Pharma Anticorpos anticinas que se ligam a múltiplas quimiocinas
JP2011097867A (ja) * 2009-11-05 2011-05-19 Kurume Univ 脊柱靱帯骨化症のマーカーペプチド
US20120315267A1 (en) * 2010-02-09 2012-12-13 Glaxosmithkline Llc Novel uses
WO2013166099A1 (en) * 2012-05-01 2013-11-07 Glaxosmithkline Llc Novel antibodies

Also Published As

Publication number Publication date
ME03094B (me) 2019-01-20
EP2970447B1 (en) 2018-05-16
CN109134652A (zh) 2019-01-04
EP2970447A1 (en) 2016-01-20
MX364831B (es) 2019-05-08
HUE038834T2 (hu) 2018-11-28
LT2970447T (lt) 2018-07-25
AU2014237898A1 (en) 2015-08-20
CN105143259A (zh) 2015-12-09
PH12015502090A1 (en) 2016-01-18
CL2015002531A1 (es) 2016-06-17
IL241167A0 (en) 2015-11-30
EP3348569A1 (en) 2018-07-18
PL2970447T3 (pl) 2018-10-31
DK2970447T3 (en) 2018-06-18
RS57291B1 (sr) 2018-08-31
AU2014237898A8 (en) 2015-08-27
IL269387B (en) 2021-05-31
WO2014149733A1 (en) 2014-09-25
PE20191480A1 (es) 2019-10-18
PE20151531A1 (es) 2015-10-28
TR201807613T4 (tr) 2018-06-21
EA029965B1 (ru) 2018-06-29
EP3608336A1 (en) 2020-02-12
JP2016512026A (ja) 2016-04-25
MA38413A1 (fr) 2017-10-31
JO3580B1 (ar) 2020-07-05
IL269387A (en) 2019-11-28
AU2014237898B2 (en) 2016-05-05
BR112015020174A2 (pt) 2017-08-29
CA2901468A1 (en) 2014-09-25
CY1120459T1 (el) 2019-07-10
HRP20181047T1 (hr) 2018-08-24
NZ711704A (en) 2019-12-20
EP3348569B1 (en) 2019-11-27
KR101745230B1 (ko) 2017-06-08
ES2769123T3 (es) 2020-06-24
TWI612059B (zh) 2018-01-21
CA2901468C (en) 2018-02-20
IL241167B (en) 2019-10-31
PT2970447T (pt) 2018-08-07
AP2015008731A0 (en) 2015-09-30
AR125831A2 (es) 2023-08-16
SI2970447T1 (en) 2018-06-29
PH12015502090B1 (en) 2016-01-18
TW201520226A (zh) 2015-06-01
TN2015000377A1 (en) 2017-01-03
HK1212714A1 (zh) 2016-06-17
EA201591514A1 (ru) 2016-03-31
KR20150119155A (ko) 2015-10-23
AR094960A1 (es) 2015-09-09
JP6105146B2 (ja) 2017-03-29
CN109134652B (zh) 2022-05-24
MX2015013053A (es) 2016-05-18
SG11201507686TA (en) 2015-10-29
MY171213A (en) 2019-10-02
CN105143259B (zh) 2018-09-21
ES2675404T3 (es) 2018-07-11

Similar Documents

Publication Publication Date Title
UA116008C2 (uk) Антитіло проти підгрупи elr+ cxc-хемокінів
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
MX2021008816A (es) Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos.
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201990346A1 (ru) Антитела к gprc5d, биспецифические антигенсвязывающие молекулы, которые связывают gprc5d и cd3, и их применение
BR112018010172A2 (pt) anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201890513A1 (ru) Антитела к bcma, биспецифические антигенсвязывающие молекулы, которые связываются с bcma и cd3, и их применение
BR112016028378A2 (pt) anticorpos contra o receptor do fator de necrose tumoral induzido por glicocorticoide (gitr) e usos dos mesmos
EA201790799A1 (ru) Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
EA202091540A1 (ru) Антитела к lilrb2
EA201891084A1 (ru) Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
EA201492101A1 (ru) Антитела против fcrn
EA201890222A1 (ru) Полиспецифические антигенсвязывающие молекулы и их применения
EA201500876A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EA200970954A1 (ru) Пентаспецифические антитела, способы их получения и применения
UY35399A (es) Conjugados de fármacos con anticuerpos
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201500818A1 (ru) Антитела к cd47, не вызывающие истощение тромбоцитов и красных кровяных телец, а также способы их применения
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv